Kymera Therapeutics had its Relative Strength (RS) Rating upgraded from 90 to 93 Wednesday.
Here Are 3 Keys For Successful Stock Investing
IBD's proprietary rating measures share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the best stocks tend to have an RS Rating north of 80 as they launch their largest price moves.
Kymera Therapeutics is not currently near a potential buying area. See if the stock goes on to build a base that could launch a new move.
The company reported 0% EPS growth in its most recent report. Sales increased 115%. Look for the next report on or around Aug. 1.
Kymera Therapeutics holds the No. 160 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and ACADIA Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
